SCHEMBL25311595

SCHEMBL25311595

Cc1nc2c(F)cc([N+](=O)[O-])cn2c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.38
ALDH1A1 P00352 7/20 0.38
LMNA P02545 5/20 0.38
GAA P10253 1/20 0.38
CHEK1 O14757 1/20 0.38
DAPK3 O43293 1/20 0.38
GRK5 P34947 1/20 0.38
LIMK1 P53667 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
S1PR4 O95977 1/20 0.35
TSHR P16473 2/20 0.34
HTT P42858 2/20 0.34
SOS1 Q07889 1/20 0.33
HIF1A Q16665 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25312423 0.85 MAPT (0.36) MAPTALDH1A1LMNAGAACHEK1
SCHEMBL25310974 0.77 ALDH1A1 (0.36) MAPTALDH1A1LMNAGAACHEK1
SCHEMBL25311294 0.76 MAPT (0.35) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL25539251 0.75 AKT1 (0.34) CYP1A2CYP2C9CYP2C19
SCHEMBL25104683 0.75 ATP4A (0.34) CYP1A2CYP2C9CYP2C19
SCHEMBL25309468 0.74 S1PR4 (0.39) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL25311822 0.73 MAPT (0.37) MAPTALDH1A1LMNAGAACHEK1
SCHEMBL25103350 0.72 NMT1 (0.33) GAACYP2C9HTT
SCHEMBL25104409 0.72 CYP3A4 (0.30) CYP1A2CYP2C9CYP2C19
SCHEMBL4311317 0.70 MAPT (0.57) MAPTALDH1A1LMNAGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092066-A1 SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2025-03-20 US disclosed
EP-4466268-A1 SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS Aurigene Oncology Limited (IN) 2024-11-27 EP disclosed
CN-118591541-A Substituted bicyclic heterocycles as MALT-1 inhibitors 奥瑞基尼肿瘤有限公司 2024-09-03 CN disclosed
WO-2023139479-A1 SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-07-27 WO disclosed
WO-2023139479-A1 SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092066-A1 SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS MALT1, FKBP1B, FKBP1A MAPT 50/4885ALDH1A1 2253/4885LMNA 3340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.